Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for the Discovery and Development of Next Generation Engineered Toxin Bodies for the Treatment of Cancer Feb 11, 2021 7:30am EST
Molecular Templates Announces FDA Acceptance of IND Application for MT-6402, a PD-L1-Targeted Engineered Toxin Body Enabled with Proprietary Antigen Seeding Technology Jan 19, 2021 8:00am EST
Molecular Templates, Inc. Reports Third Quarter 2020 Financial Results and Provides a Corporate Update Nov 05, 2020 4:30pm EST
Molecular Templates, Inc. Raises $43 Million in Gross Proceeds Through Its At-the-Market Facility Jul 20, 2020 4:30pm EDT
Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2020 Highlight Evolution of ETB Platform Jun 22, 2020 7:30am EDT
